Prelude Therapeutics, Incorporated

Prelude Therapeutics, Incorporated is a clinical-stage precision oncology company dedicated to discovering and developing innovative medicines for cancer patients with high unmet needs. Founded in 2016, the company's mission is to extend the promise of precision medicine to every cancer patient. Its corporate headquarters are located in Wilmington, Delaware, at 175 Innovation Boulevard.

The company's pipeline is focused on novel small molecule candidates, including highly selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, which represent new approaches to clinically validated targets. Prelude Therapeutics also leverages its expertise in targeted protein degradation to develop next-generation degrader antibody conjugates (DACs) with novel payloads. Key programs include PRT13722, a KAT6A degrader, and PRT12396, a JAK2V617F inhibitor.

Recent notable developments include the pricing of a $90 million stock offering in April 2026. In the same month, Prelude Therapeutics presented promising preclinical data for PRT13722 at the American Association for Cancer Research (AACR) Annual Meeting, demonstrating its potential efficacy in HR+/HER2- breast cancer models. The company also appointed Dr. Charles Morris as Chief Medical Officer in April 2026. Furthermore, the FDA cleared the Investigational New Drug (IND) application for PRT12396 in the first quarter of 2026, with a Phase 1 trial anticipated to begin by the second quarter of 2026. Kris Vaddi, Ph.D., serves as the Chief Executive Officer and founder of Prelude Therapeutics.